Thermo Fisher Launches Bioreactor, Expands Hydration Line

Thermo Fisher Scientific (NYSE:TMO) has introduced the Gibco CTS DynaXS Single Use Bioreactor, targeting cell therapy manufacturing. The company has opened its flagship U.S. Bioprocess Design Center in Massachusetts to support biologics and advanced therapy development. Thermo Fisher is a top vendor in the growing DNA synthesis market and is expanding its Nalgene Outdoor hydration product line. The current share price stands at $465.0.

The Product

The Gibco CTS DynaXS bioreactor features single-use technology, reducing contamination risks and accelerating manufacturing processes. It is designed for biotech firms working on cell and gene therapies, providing a sterile, controlled environment for cell expansion.

Pricing and Availability

Pricing has not been disclosed, but the bioreactor is expected to be available for order starting Q3 2026. The Bioprocess Design Center in Massachusetts is operational and already accepting industry partners.

Competition

Thermo Fisher faces competition from Sartorius and Merck KGaA in the single-use bioreactor space, but its extensive supply chain expertise and vertical integration provide a competitive edge.

Potential Impact on the Company

These expansions are expected to strengthen Thermo Fisher's position in the rapidly growing bioprocessing market, particularly as demand for cell and gene therapies rises. The Nalgene hydration line expansion could also diversify revenue streams.